argenx’s VYVGART Shows Clinically Meaningful Benefit in Phase 3 Myositis Study, Stock Jumps
argenx’s efgartigimod met primary endpoint in Phase 3 ALKIVIA trial for autoimmune myositis, showing 15.4-point TIS improvement at Week 52.
/ 5 items
#ARGX↓
Argenx Expands Immunology Pipeline with $2.2B Forte Deal
Argenx acquires Forte Biosciences for $77/share, adding the first-in-class FB102 anti-CD122 antibody to expand its immunology pipeline for autoimmune diseases.
Immunovant’s Batoclimab Flops in Phase 3 Thyroid Eye Disease Trials
Immunovant’s batoclimab failed key TED trials, but high doses helped; focus now shifts to next-gen drug IMVT-1402 for autoimmune disease.
Wolfe Research Upgrades Immunovant to Outperform with $50 Target
Wolfe Research upgrades Immunovant stock, citing higher valuation support, declining short interest, and positive catalysts ahead in 2026.
argenx Stops Thyroid Eye Disease Studies
argenx discontinues Phase 3 trials of efgartigimod SC for thyroid eye disease after independent review finds treatment unlikely to meet goals. Safety profile remained favorable.